Results 91 to 100 of about 37,277 (211)

Assessment of Selected Clinical Chemistry Analytes Among Hypertensive Patients at Wallaga University Referral Hospital, Nekemte, Oromia, Western Ethiopia: A Comparative Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Hypertension (HTN) is a long‐term condition marked by consistently high arterial blood pressure. It is a leading contributor to cardiovascular diseases and early mortality around the globe. It increases the risk of ischemic heart disease, stroke, chronic kidney disease (CKD), and dementia.
Amanuel Hika, Sintayehu Asaye Biya, Temam Ibrahim Husen, Negesse Bokona Rufe, Hundesa Emana Urgesa, Bedasa Addisu   +5 more
wiley   +1 more source

A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non‐Small Cell Lung Cancer With Cachexia (SPIRAL‐ANA)

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 4, August 2026.
ABSTRACT Background The prognosis of patients with advanced non‐small cell lung cancer (NSCLC) complicated by cancer cachexia remains poor. Anamorelin, a ghrelin receptor agonist, has been approved only in Japan for the treatment of cancer cachexia.
Kenji Morimoto, Junji Uchino, Makoto Hibino, Yuki Takeyasu, Ken Yamamoto, Yoshie Morimoto, Yusuke Chihara, Takayuki Nakano, Hiroyasu Kaneda, Shunya Tanaka, Shinsuke Ogusu, Yasuhiro Goto, Takashi Nomizo, Takayo Ota, Hiroaki Tsukamoto, Yoshizumi Takemura, Katsumi Nakatomi, Hayato Koba, Kohei Yoshimine, Takayuki Shimose, Tadaaki Yamada, Koichi Takayama   +21 more
wiley   +1 more source

Examining the significance of arginine vasopressin release to elucidate the often multifactorial etiology of hypotonic hyponatremia: A novel criterion

Physiological Reports
Clinical hyponatremia guidelines, protocols and flowcharts are a convenient means for clinicians to quickly establish an etiological diagnosis for hyponatremia, and facilitate its often complex analysis.
Philip J. G. M. Voets
doaj   +1 more source

Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2‐Year Follow‐Up From MajesTEC‐1 China Cohort

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction With an additional year of follow‐up compared with the previous report, this study presents the 27.2‐month efficacy and safety outcomes of the MajesTEC‐1 China cohort. Methods A total of 26 participants with triple‑class exposed relapsed/refractory multiple myeloma (TCE‐RRMM) received subcutaneous teclistamab 1.5 mg/kg weekly ...
Zhen Cai, Zhongjun Xia, Aili He, Yujun Dong, Yafei Wang, Aijun Liao, Yang Song, Hongye Chen, Athena Zuppa, Katherine Chastain, Latisha Watkins, Xinchao Luo, Lin Huang, Hongmei Xu, Longen Zhou, Wannan Chen, Angeline Zhu, Xiaohong Wang, Weijun Fu, Ting Niu, Juan Du   +20 more
wiley   +1 more source

Safety and Efficacy of Aumolertinib as First‐Line Treatment in EGFR‐Mutant Lung Adenosquamous Carcinoma: A Multicenter, Single‐Arm, Prospective Phase II Study (ARISE Study)

MedComm, Volume 7, Issue 8, August 2026.
Aumolertinib treatment resulted in improved clinical activity in EGFR‐mutant ASC. ABSTRACT Lung adenosquamous carcinoma (ASC) is a rare histological subtype of non‐small cell lung cancer (NSCLC), and prospective data regarding the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in this patient population remain ...
Longfeng Zhang, Long Huang, Dingzhi Huang, Zhe Liu, Yongfeng Yu, Kang Miao, Qian Miao, Xiaobin Zheng, Yiquan Xu, Qian Chu, Gen Lin   +10 more
wiley   +1 more source

First‐In‐Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck

Cancer Science, Volume 117, Issue 8, Page 2247-2258, August 2026.
The dose escalation part of the first‐in‐human study of E7130 in patients with advanced solid tumors determined the Recommended Phase 2 Dose of E7130 (480 μg/m2 Q3W). The dose expansion part (presented here) examined safety/preliminary efficacy in patients with squamous cell carcinoma of the head and neck and urothelial carcinoma.
Nobuaki Matsubara, Ken Saijo, Yasushi Shimizu, Susumu Okano, Kenji Nakano, Naoki Nishio, Tomoyuki Otsuka, Hirofumi Kuno, Takuma Miura, Tomoki Kubota, Hiroki Ikezawa, Yuko Umetsu, Ken Ito, Abraham Apfel, Yuanqing Ye, Yoshitaka Honma   +15 more
wiley   +1 more source

Mutational Signature‐Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High‐Grade Ovarian Cancer

Cancer Science, Volume 117, Issue 8, Page 2259-2273, August 2026.
A whole‐exome sequencing–based mutational signature biomarker (MSBM) identified an HRD‐enriched population in advanced ovarian cancer. In a phase II trial, olaparib maintenance suggested clinically meaningful PFS benefit without bevacizumab, supporting MSBM as a complementary HRD assessment approach.
Katsutoshi Oda, Daisuke Shintani, Akira Nishijima, Mayuyo Mori, Kazuyoshi Kato, Shoji Nagao, Noriomi Matsumura, Masahiro Kagabu, Masataka Takenaka, Kosuke Yoshihara, Yosuke Konno, Junzo Hamanishi, Sho Sato, Shiro Takamatsu, Keiko Ueda, Kosuke Kashiwabara, Takashi Aoki, Kunihiro Nishimura, Kenji Tatsuno, Hiroyuki Aburatani, Kosei Hasegawa   +20 more
wiley   +1 more source

Identification of Frailty Subtypes in African American Adults With and Without Type 2 Diabetes: A Latent Class Analysis From the Jackson Heart Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7218-7226, August 2026.
ABSTRACT Aims To identify frailty subtypes among African American adults with and without diabetes. Methods This analysis included data from 3979 African American men and women who enrolled in the Jackson Heart Study at baseline (Exam1: 2000–2004). To identify frailty subtypes, we selected 25 age‐related deficits in health and functional outcomes as ...
Felicia R. Simpson, Mark A. Espeland, Alain G. Bertoni, Jai J. Legins, Torre S. Lloyd, Tanaiya A. Sumter   +5 more
wiley   +1 more source

Characterization of Usage Patterns of Drugs Suspected to Cause Adverse Drug Reactions in Older Hospitalized Patients

Geriatrics &Gerontology International, Volume 26, Issue 8, August 2026.
ABSTRACT Aim This study aimed to characterize the usage patterns of drugs suspected to cause adverse drug reactions (ADRs) in older hospitalized patients. Methods Medical records of older adults admitted to the Department of Geriatrics and Hypertension at Osaka University Hospital from September 2014 to August 2021 were reviewed.
Mizuki Katsuhisa, Shota Hamada, Chie Hamaie, Yuko Takeshita, Kasumi Ikuta, Yuichiro Saizen, Eriko Koujiya, Yoichi Takami, Koichi Yamamoto, Yasushi Takeya   +9 more
wiley   +1 more source

Hyponatremia

Western Journal of Medicine, 2002
Jameela, Al-Salman, David, Kemp, Daniel, Randall   +2 more
openaire   +3 more sources